| Hans-Günter Meyer-Thompson | Buprenorphin
CLINICAL GUIDELINES FOR USE OF DEPOT BUPRENORPHINE (BUVIDAL®) IN THE TREATMENT OF OPIOID DEPENDENCE
CLINICAL GUIDELINES FOR USE OF DEPOT BUPRENORPHINE (BUVIDAL®) IN THE TREATMENT OF OPIOID DEPENDENCE
This Clinical Guideline has been developed to inform decision-making by clinicians prescribing and/or patients being treated with Buvidal® long-acting injected buprenorphine preparations.
This guideline was funded by Camurus Ltd. The funding enabled SMMGP to provide clinical, managerial, editorial and administrative input. (SMMGP - Substance Misuse Management in General Practice, UK, April 2020)
https://www.smmgp-fdap.org.uk/clinical-guidelines-for-use-of-depot-buprenorphine-buvidal-in-the-treatment-of-opioid-dependence